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ABSTRACT 
Artificial Neural Network (ANN) technology is a group of computer designed algorithms for simulating neurological processing to process 
information and produce outcomes like the thinking process of humans in learning, decision making and solving problems. The uniqueness of ANN 
is its ability to deliver desirable results even with the help of incomplete or historical data results without a need for structured experimental design 
by modeling and pattern recognition. It imbibes data through repetition with suitable learning models, similarly to humans, without actual 
programming. It leverages its ability by processing elements connected with the user given inputs which transfers as a function and provides as 
output. Moreover, the present output by ANN is a combinational effect of data collected from previous inputs and the current responsiveness of the 
system. Technically, ANN is associated with highly monitored network along with a back propagation learning standard. Due to its exceptional 
predictability, the current uses of ANN can be applied to many more disciplines in the area of science which requires multivariate data analysis. In 
the pharmaceutical process, this flexible tool is used to simulate various non-linear relationships. It also finds its application in the enhancement of 
pre-formulation parameters for predicting physicochemical properties of drug substances. It also finds its applications in pharmaceutical research, 
medicinal chemistry, QSAR study, pharmaceutical instrumental engineering. Its multi-objective concurrent optimization is adopted in the drug 
discovery process, protein structure, rational data analysis also. 
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Artificial intelligence (AI) has been brought into existence for 
generating programming equipped for modern, wise, calculations 
like those that the specific brain routinely performs. It incorporates 
techniques, instruments, and frameworks to re-enact human 
strategies for legitimate and inductive learning procurement by 
brain activity of solving problems. Artificial intelligence is helpful for 
restorative finding and other demonstrative critical thinking. It gives 
a guide to expectation including vulnerability and ambiguity.  
The following review was concentrated to elaborate the artificial 
neural networks in detail and its applications in the pharmaceutical 
field. Review and research article on ANN and its components that 
are available in journal databases such as Science Direct, Proquest, 
Springer from the year 2000-2018 were studied and in-depth 
knowledge on ANN was produced. Very few articles before the year 
2000 were also considered. 
Artificial Neural Network (ANN), an advancement of AI, are digitized 
models of a human brain, in which computer programs intended to 
mimic the way in which human brain forms data for desired 
outcome [1-2]. ANN perform through repeated or previous 
experience with suitable learning models similarly as individuals 
think, but not from programming. In other words, an ANN is a 
biologically developed computational model shaped from many 
single units, artificial neurons, associated with coefficients (weights) 
which constitute the structural neuron [3]. They are otherwise 
called processing elements (PE) as they process data. Every PE has 
an input of various weights, transfer function and gives as one 
output [4]. ANN has the capacity of handling broad measures of 
information, in any case, and making expectations that are very 
accurate. However, this does not make them keen on the usual 
'human' feeling of the word, so computer knowledge might be a 
better method for depicting these functions. There are numerous 
sorts of neural systems planned at this point, and new ones are 
created every week. However, all can be represented by the 
exchange elements of their neurons, by the learning rule and 
connection formula [5]. ANN performs when the given data, called 
inputs are processed through a transfer function to deliver the 
output for that neuron, and the most ordinarily utilized exchange 
work is the sigmoid work. Dynamic networks can store information 
and expand it in time that is the favourable position of dynamic 
neural networks (contrasted with the static networks). Each input is 
investigated as a capacity of the previously submitted input [6]. The 
system recollects history; subsequently, the present output is 
coordination of previous data and the currently processed data of 
the system [7]. The neurons get several inputs, and it performs 
computation depending on the primitive function mentioned on the 
body of the neurons and depending on the threshold value 
mentioned the network decides whether to signal output or not. [8]. 
 
Fig. 1: Pictographic representation of four layered ANN 
network [3] Learning in ann 
 
Among the various learning methods of ANN, Backpropagation rule 
[9] or delta rule is regularly utilized. The ANN reads the value of 
input and output from the training set of data and changes the 
estimation of the weighted connects to decrease the contrast 
between the anticipated and target esteems [10-11]. The blunder in 
expectation is limited to many training cycles until the point that the 
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system achieves indicated the level of accuracy. Preparing a system 
for more extended periods will results in overtraining, eventually 
losing its ability to perform the prescribed function. 
Connection formula 
The neurons which link with each other has a significant impact on 
the processing of ANN. These neurons can get either excitatory or 
inhibitory data sources [12]. Excitatory information causes the 
summing system of the next neuron to include while the inhibitory 
information sources make it subtract. The system needs to 'pick' the 
most probability and repress all others, which is called as 
competition. Feedback is another connection where the output of 
one layer courses back to the contribution of a past layer, or to the 
same layer. Every neuron has extra leverage as information that will 
permit an extra level of flexibility when attempting to limit the 
preparation mistake. Such a system keeps a memory of past state, so 
that next state depends not just on input signal [13] yet additionally 
on the previous conditions of the system. 
 
 
Fig. 2: Neuron transmission process model [3] 
 
Approaches in ann 
There are two ways to deal with training, i.e., supervised and 
unsupervised. The most frequently utilized ANN is a completely 
associated supervised network with back propagation learning 
standard [14]. Supervised learning is a type of relapse that depends 
on case sets of information where the input layer neurons get 
information from a document, and the output neurons give ANN 
reaction to the data. Processing neurons discuss just with different 
neurons and then decide an answer to the issue. This approach 
focuses mainly on the predicting one or more input variables. In case 
of unsupervised training, the system is given with inputs but not 
with the fixed output. The framework itself should then choose what 
feature will be required to enlist the input data. Therefore, this 
approach is called as adaptation or self-organization [15]. The goal 
of this approach is to develop a variable from which the observed 
variable, both input and output factors, can be anticipated. 
Application of artificial neural network in the field of 
pharmaceutical aspects 
The artificial neural network finds its application in the various fields 
of pharmaceutical sciences. Some of them are enlisted as below:  
Structural screening in drug discovery process 
The standard approach to predicting how active a chemical 
compound will be against a given target (usually a protein that 
needs to be inhibited) in the development of new medicines is to use 
machine learning models [16]. ANN-based QSAR models are broadly 
picked as the forecast strategies in the virtual screening. The 
essential part of Artificial Intelligence in patient care is quiet finding 
and picture examination, the future holds incredible potential for 
applying AI to enhance numerous parts of the patient care handle 
[17]. This approach is referred to as virtual screening. For example, 
if any basic structure of the compound is the input for a neural 
network, it displays various structure similar to those compounds 
screens over 1000 compounds, among them three compounds with 
high biologic activity can be identified [18]. 
Toxicity prediction  
ANN can be used as an integral part of pharmacotoxicology, 
especially in Quantity Structure Toxicity Relationship (QSTR) 
contemplates. QSTR is a connection between the substance 
descriptors and its toxicological activity and can be associated to 
predict the lethality of compounds [19]. Like QSAR, the molecular 
descriptors of QSTR are predicted from physicochemical properties 
of the compounds and related to a toxicological reaction of intrigue 
through ANN. For example, topology method used as the input mode 
of a network; The ANN-QSTR model was approved by 23 substituted 
benzene derivatives. The connection coefficient amongst anticipated 
and real toxicological activities of these compounds was observed to 
be 0.9088 [20]. 
Designing of preformulation parameters 
ANN modelling has been utilized to enhance pre-formulation 
parameter and to estimate the physicochemical properties of 
amorphous polymers. They predict the absorption, glass 
temperatures and viscosities of different hydrophilic polymers and 
their physical substance with a low expectation mistake (0-8%) [21]. 
It demonstrated the potential of ANN as a preformulation tool by 
prediction of the relationship between the composition of polymer 
substance and the water uptake profiles, a viscosity of polymers 
solutions, moisture content and their glass transition temperatures. 
[22]. In the presence of multiple Active Pharmaceutical Ingredient 
(API) this model could test 14 APIs after progressing the strategy of 
utilizing self-sorting out maps recognizing the goal to extend the 
database of quick release tablet and to concentrate the impact of 
Programming interface on the tablet properties [23-24]. It has been 
precious in the pre-formulation outline and would help to decrease 
the cost and length of preformulation contemplate. 
Optimization of pharmaceutical formulation 
It addresses the multi-objective oriented concurrent optimization 
issues in the pharmaceutical industry to establish the relationship 
between reaction factors and insignificant factors [25]. The 
prediction of pharmaceutical responses in the polynomial equation 
and response surface methodology (RSM) has been broadly used as 
a part of formulation optimization [26-27] However; this prediction 
is small scale due to a low success rate of estimation. An 
optimization method consolidating an ANN has been created to 
overcome these shortcomings and to anticipate release profile and 
improve detailing of different drug formulations. For example, 
aspirin or diclofenac sodium prolonged-release tablets [28-29]. The 
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results calculated by the trained ANN model satisfy well with the 
theoretically observed values including in vitro release pattern 
which helps to improve the effectiveness of process and formulation 
variables. 
Quantity structure-activity relationship (QSAR) 
ANN has been shown to be a useful tool to establish this type of 
relationship and predict the activities of new compounds [30]. QSAR 
links physicochemical parameters of compounds with substance or 
biological activities [31-32]. These parameters include molecular 
weight, log p-value, electronic properties, hydrophobicity, steric 
effects, a hydrogen donor, molar volume and molar refractivity. 
Experimental determination of such properties can be the time-
consuming process, and in a few cases, there may occur 
experimental variation and errors [33]. An initial phase in QSAR 
contemplates figuring a massive number of structural descriptors as 
mathematical illustrative of chemical structure [33]. The relation of 
structure and activity with the physicochemical descriptors and 
topological parameters can be controlled by computational 
techniques. For example, ANN has been utilized by Grobburu and 
associates to foresee the quantitative structure QSPR of beta-
adrenoceptor antagonist in human [32]. In the examination, ANN 
with the congeneric arrangement of ten beta-blockers having high 
set up pharmacokinetic parameters was developed and tried for its 
ability to predict the pharmacokinetic parameters [33-34]. Testing 
an enormous number of possible combination of descriptors might 
take a lifetime to succeed. A more efficient path is to utilize 
algorithm calculations such as computational models of 
advancement, combined with Artificial Neural Network [35-36]. 
"Back-propagation (ANN) were trained with topological indices, 
molecular connectivity, and novel physicochemical descriptors to 
predict the structure-activity relationship of a large series of 
analogues" [37-41]. It generates valuable models of the aqueous 
solubility inner arrangement of fundamentally related medications 
with necessary auxiliary parameters [42]. Topological descriptors 
interface the compounds with their aqueous solubility [43]. ANN 
predicted properties exhibited better correlation with the 
experimentally determined values than those predicted by various 
multiple regression methods. Correlation studies of the prescient 
performance of an automated model with an observational ANN 
display in ascertaining the connection between the tissue 
distributions furthermore, the lipophilicity of a homologous 
arrangement of 5-n-alkyl-5-ethyl barbituric acids in the rats have 
been distributed and exhibited the scope of ANN in this application 
[43]. Further, ANN has been valuable in QSAR investigation of 
antitumor movement of acridinone subordinates [44]. Moreover 
developed mode allowed to recognize the critical variables adding to 
the antitumor movement such as lipophilicity. Therefore, ANN is not 
just valuable in predicting QSARs yet additionally in distinguishing 
the part of the particular components relevant to the action of 
interest. It has been exhibited in the earlier investigation by Uesawa 
also, partners in their QSAR investigation of tumor-specificity of 
1,2,3,4-tetrahydroisoquinoline subordinates [45]. ANN can also be 
exceptionally helpful in predicting synthetic properties of 
compounds. A few research groups have displayed the typical 
breaking point of hydrocarbons. Predicting neural system models 
have been distributed for alkanes, alkenes, and assorted 
hydrocarbons. Of course, the models commonly demonstrate great 
fitting and expectation insights with under ten necessary 
descriptors. Goll and Jurs also connected the simulated neural 
system to anticipate the vapor weights of hydrocarbons and halo 
hydro-carbons from sub-atomic structure [46]. 
Pharmacokinetics and pharmacodynamics 
ANN monitors human pharmacokinetics parameters from the set of 
data on physicochemical properties of medications such as partition 
coefficient, protein binding, dissociation constant and animal 
pharmacokinetic parameter [47-48]. Medication doses and drug 
choice are resolved by information of the drug's pharmacokinetics 
and pharmacodynamics [49]. They are adapted to estimate the 
pharmacodynamics profiles precisely for a broad assortment of 
pharmacokinetic and pharmacodynamics relationship without 
requiring any data of active metabolite [50-52]. As they do not 
require any structural information, it provides an idea over usual 
dependent conventional methods. ANN is a quick and 
straightforward method for predicting and identifying covariates 
[53-54]. For example, the rate of clearance, protein-bound fraction 
of drug and also volume distribution can be determined by 
incorporating them in monitoring various PK interactions in the 
biological system and anticipation of PD parameters. Because of 
their computational adaptability, they have been used as a tool for 
population pharmacokinetic investigation and result concludes ANN 
as a better estimate tool in comparison with NONMEM. Hussain et al. 
used ANN in the prediction of PK parameters from data obtained in 
animal studies. Further, Ritchel et al. predicted human PK 
parameters utilizing information from the data set of 
physiochemical properties like dissociation constant, protein 
binding, a volume of distribution, partition coefficient in association 
with animal PK parameters [55]. Corrigan et al. connected neural 
system to predict the concentration of gentamicin in a general 
doctor's facility population [56]. Their outcomes demonstrated that 
neural networks offered a few favorable advantages over traditional 
dose prediction techniques. Kenji et al. connected an ANN simulation 
to link the pharmacokinetic of aminoglycoside anti-microbial 
utilizing physiological estimation in patients with extreme disease 
[57]. 
Proteomics and genomics 
In the detachment of peptides in ion exchange chromatography, 
ANN predicts peptide separation. Due to their ability to identify the 
pattern, ANN is appropriate for the arrangement of proteins, 
prediction of enzyme class, characterization of DNA/RNA and 
protein [58]. A hierarchical network named PRED-CLASS have been 
used to group proteins into four categories, for example, 
transmembrane, stringy, globular and blended proteins. The PRED-
CLASS prepared by studying 50 protein arrangements, predicted 
371 out of an arrangement of 387 proteins with an accuracy of 96 
percent [59]. These properties are highly significant in the 
investigation of protein structure and function. They could assist in 
the prediction of protein tertiary structure, for example, a data of six 
input and six hidden units with sigmoid transfer function developed 
by Murvaiet et al. for the acknowledgment of areas in protein 
succession [60]. Cai and colleagues utilized ANN for predicting 
secondary protein structure to pair coupled amino acid sequence. 
Furthermore, the study exhibited that ANN is an appropriate 
technique for prediction of the secondary structure of proteins. The 
neural systems have been utilized to predict eukaryotic protein 
phosphorylation sites to identify active sites and to predict protein 
class with high accuracy for novel protein structures in peptide 
sequence and enhancement protein confinement and arranging 
prediction [61]. Additionally, ANN-based algorithms have been 
utilized to recognize, characterize and anticipate stabilization center 
elements from the essential structure of single proteins and amino 
acid sequence of homologous proteins. 
Disease diagnosis 
ANN has been applied in the diagnosis of various diseases by the 
input of clinical data [62]. It exhibits good results in the early 
prediction of cardiovascular risk or myocardial infarction, diagnosis 
of Alzheimer's disease, prediction of outcome in epilepsy surgery, 
prediction of development of pregnancy-induced hypertensive 
disorders, diagnosis of pigmented skin lesions Moreover, it has also 
been used to predict responses in pharmacotherapy, hormonal 
treatment in metastatic breast malignancy and clinical result for 
individual patients [63-68]. Compared to conventional strategies, 
the level of certainty for the prediction can achieve 90% by 
employing ANN [70, 71], and this can make a significant 
advancement towards individualized treatment in the future. 
In vitro in vivo correlation 
The in vitro in vivo relationships (IVIVC) are of great interest to the 
pharmaceutical industry to dodge bioequivalence subjects which 
exhibits considerable variability in results. They can predict the IVIVC 
of the same product with different formulations and also they can skip 
constraints related to regression methods. For example, the absence of 
design acknowledgment powers breaking down multivariable 
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informational collections with the high level of variety [72-75]. 
Jovanovic et al. determine IVIVC of salbutamol in the lungs in healthy 
and asthmatic volunteers even without in vivo information. The 
medication drug level was estimated in urine and compared with the 
pulmonary function. The investigation inferred that ANN is helpful in 
anticipating in vivo reaction with given in vitro information [76]. 
 
Table 1: List of neural networking software 
Software Applications 
Statistica Neural network 
 
Signal processing, and Classification, Pattern recognition, Medical diagnostics and monitoring, 
Image and speech analysis, Stock market and forecasting [77] 
Tns2server 
Applied Analytic System, Inc. 
Genetic Algorithm solutions, Statistical Analysis, Linear and Nonlinear Optimization, Mathematical 
modeling 
Data engine Functionality for all the phases of data analysis 
Environment for Computer-Aided Neural 
Software Engineering (eCANSE) 
Data Analysis, Experiment design and actual experimentation, Analyzing and packaging results [78] 
Fast Artificial Neural Network (FANN) Backpropagation training, Evolving topology training, Graphical interface 
Brian Neural Network simulator Plotting and analysis of auditory system modelling, Electrophysiological data 
Neural Simulation Language Supporting neural network layer, Programming of neural elements 
Neuroshell Large library of technical analysis, Prediction analysis, Genetic Optimization and Multicore 
Distributed Optimization, Multiple Time Frame analysis, Batch Processing [79] 
 
Conclusion and future perspectives  
The application of ANN in pharmaceutical development can be 
successfully applied in various fields especially pattern 
classification, function approximation, optimization, prediction of 
improved therapeutic effect. Adapting in the pharmaceutical area 
have been of great interest due to its capacity to design a process 
that can't be satisfactorily represented by statistical methods. Its key 
advantage falls in the process of drug discovery in pharmaceutical 
research by viewing the accurate data prediction. At present, ANN 
has the potential to predict toxicity, physicochemical and biological 
activity and diagnosis of disease. Furthermore, ANN it was already 
successfully applied in some of the pharmaceutical processes such 
as medicinal chemistry, clinical chemistry, the study of 
pharmacokinetic aspects to provide solutions for large-scale 
manufacturing and improvement of physical and biological 
properties by ANN suggested modifications. 
ABBREVIATIONS 
AI = artificial intelligence, ANN = artificial neural network, API 
=active pharmaceutical ingredient, eCANSE= environment for 
computer aided neural, software engineering, FANN= fast artificial 
neural network, IVIVC= in vitro in vivo correlation, PE= processing 
elements, PD= pharmacodynamics, PK= pharmacokinetics, QSAR= 
quantitative structure-activity relationship, QSPR = quantitative 
structure-property relationship, QSTR= quantitative structure-
toxicity relationship, RSM= response surface methodology. 
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